ReviewSmall (Weinheim an der Bergstrasse, Germany)2026
Precisely Engineering Biomimetic Nanoparticles via Controlled Cell Membrane Coating.
Review in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cell membrane-coated nanoparticles (CMNPs) represent an advanced class of biomimetic nanomaterials that integrate the functional complexity of natural cell membranes with the tunable properties of synthetic nanoparticle cores. By inheriting native membrane proteins, lipids, and glycans, CMNPs exhibit attractive properties such as enhanced immune evasion, prolonged circulation, and cell-specific interactions, thereby supporting a wide range of therapeutic, diagnostic, and biomedical applications. However, precise control over CMNPs fabrication remains challenging, particularly with respect to particle size, membrane coating integrity, and membrane leaflet orientation, all of which critically influence biological performance. This review focuses on recent progress in engineering CMNPs with precise control over size, coating integrity, and membrane leaflet orientation. It first analyzes how synthetic parameters influence the particle size and size distribution of CMNPs, then outlines strategies to improve membrane coating integrity together with the corresponding evaluation methods and discusses approaches to regulate membrane leaflet orientation and the analytical techniques used for its assessment. Finally, this review highlights remaining challenges and future directions for the rational design of CMNPs, supporting their continued development toward translational nanomedicine applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.